Fortrea Holdings/$FTRE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Fortrea Holdings
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
- Ticker
- $FTRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14,000
- Headquarters
- Durham, United States
- Website
- www.fortrea.com
Fortrea Holdings Metrics
BasicAdvanced
$2.1B
-
-$0.73
1.91
-
Price and volume
Market cap
$2.1B
Beta
1.91
52-week high
$26.16
52-week low
$8.55
Average daily volume
2M
Financial strength
Current ratio
0.969
Quick ratio
0.876
Long term debt to equity
2.04
Total debt to equity
2.101
Interest coverage (TTM)
0.55%
Profitability
EBITDA (TTM)
118.1
Gross margin (TTM)
20.00%
Net profit margin (TTM)
-2.58%
Operating margin (TTM)
1.70%
Effective tax rate (TTM)
-30.36%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
1.03%
Return on equity (TTM)
-12.34%
Valuation
Price to revenue (TTM)
0.776
Price to book
3.98
Price to tangible book (TTM)
-2.14
Price to free cash flow (TTM)
12.24
Free cash flow yield (TTM)
8.17%
Free cash flow per share (TTM)
1.794
Growth
Revenue change (TTM)
-3.38%
Earnings per share change (TTM)
-93.51%
3-year revenue growth (CAGR)
-2.70%
3-year earnings per share growth (CAGR)
1.43%
What the Analysts think about Fortrea Holdings
Analyst ratings (Buy, Hold, Sell) for Fortrea Holdings stock.
Analyst projections of the future price of Fortrea Holdings stock.
Bulls say / Bears say
Quarterly and trailing book-to-bill were both 1.12x, with $773 million of new awards; Fortrea also raised the midpoints of its 2026 revenue and adjusted EBITDA outlook. That suggests bookings are replenishing work and supports a gradual return to growth. (GlobeNewswire)
Adjusted EBITDA rose 14.4% year on year and its margin widened to 8.4% from 7.2%, while quarterly free cash flow was $52.5 million. Continued cost control and better study mix are lifting profitability even before revenue growth returns. (GlobeNewswire, The Motley Fool)
Fortrea’s $45 million acquisition adds a 200-bed Texas clinical unit, an in-house bioanalytical lab and more than 570 beds across its network. These capabilities broaden its early-phase offering and could help it win more integrated work from clients. (GlobeNewswire)
Third-quarter revenue fell 1.4% year on year to $691.5 million, and revenue for the first nine months was also lower than a year earlier. Slower pass-through conversion and softer demand in functional-service work continue to hold back top-line growth. (GlobeNewswire, The Motley Fool)
Fortrea cut reported backlog by $558 million after reviewing inactive studies and contract scope. The revision highlights uncertainty in how much of the headline backlog will ultimately convert into revenue, even though the company said it does not change near-term guidance. (GlobeNewswire)
Net leverage was 3.9x and gross debt stood at about $1.07 billion at quarter end. That debt load leaves less room for setbacks, while GAAP net income was only $0.6 million in the quarter despite adjusted net income of $27.9 million. (The Motley Fool, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Fortrea Holdings Financial Performance
Revenues and expenses
Fortrea Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
Fortrea Holdings News
AllArticlesVideos
Funds containing Fortrea Holdings
Fund name | Fund size | $FTRE weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.20% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.20% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.19% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.